The most concrete AI-in-medicine claim in this week's material is also the most modest. Radical Numerics says AI-designed viruses have treated the startup's first patient, with an experimental treatment aimed at drug-resistant E. coli.1 It is one patient and a company statement, not a trial result. It still marks a shift: AI discovery work is reaching people, at the same moment the money that funds it is getting harder to raise.1
That is the tension this piece examines. Clinical and AI-enabled progress is real. So is a tighter funding climate. The companies best placed to ride it out are the ones with cash already on the balance sheet and late-stage data in hand.
The funding backdrop turned on the technology sector first
On October 30, 2026, a $1 trillion tech selloff deepened fears of an AI bubble as big AI bills and weak earnings spooked investors. The Nasdaq 100 had its worst day since June.2 The next day, OpenAI cut its funding target by $10 billion.3 On November 1, Binance users withdrew $3.6 billion when the exchange reopened after a hack.4
These are three separate events. We do not claim one caused the others. Together they describe a market that is demanding proof of returns from AI spending. For AI-driven drug discovery, which burns cash long before it earns any, that matters more than for most sectors.
What late-stage data looks like
The clearest example of data that can attract funding comes from Vor Bio. On October 22, 2026, the company announced final two-year results from its Phase 3 TELIGAN trial of telitacicept in IgA nephropathy. The annualized decline in kidney filtration (eGFR) was -0.6 in the treatment group against -5.7 mL/min/1.73 m² per year for placebo, a difference of 5.1 (p<0.001).5 Risk of confirmed 30% and 40% eGFR declines fell by 89% and 81%, and the company reports a favorable safety profile.5 This is a company press release. The release came via NewsEOD, a feed where 54% of 6,663 checked claims held up in our measurement, so we treat it as an unaudited company statement.5
Nothing in Vor's data is AI-related. It is included because it shows what an investor can price today: a controlled trial, a clear gap versus placebo and a finished two-year readout.
Early-stage gene editing: the long wait for data
Scribe Therapeutics sits at the other end of the maturity curve. Its third-quarter 2026 report, dated November 12, says it listed on the Nasdaq Global Market under the ticker SCTX and raised capital to fund early development of three programs. It also says it continues enrolling a first-in-human Phase 1 trial of STX-1150, an epigenetic silencing therapy for lowering LDL cholesterol, with initial data expected in the first half of 2027.6 The company also says it expanded its collaboration with Sanofi.6
Scribe frames the opportunity this way: current LDL-lowering therapies are limited by poor persistence, with 50% to 70% of patients stopping within one year.6 It adds that people with naturally occurring PCSK9 loss-of-function variants have been reported to have 28% lower mean LDL-C and up to 88% lower coronary heart disease risk, and that STX-1150 aims to mimic that protection.6 These are the company's own claims and its trial has produced no efficacy data yet. A cash figure for Scribe appeared in the topic brief, but we could not trace it to a source document, so we do not repeat it.
Where the cash actually is: Incyte
Incyte, which develops Jakafi, Opzelura and pemigatinib,7 offers a verified picture of what a funded runway looks like. Its cash balance, checked against SEC filings, was $3.21 billion at the end of fiscal 2023 and fell to $1.69 billion at the end of fiscal 2024.8 It recovered to $3.10 billion at the end of fiscal 2025.9 It stood at $3.46 billion in the first quarter of 2026, $3.98 billion in the second quarter and $3.28 billion in the third.10
The swing is the story. Incyte went from a cash low of $987 million in the second quarter of 2024 to nearly $4 billion two years later.11 That is a company that has funded itself through a cycle, not one waiting on the next raise. Our reading, not a figure from the filings: a $3.28 billion balance would cover Incyte's annual capital spending of $48.7 million about 67 times over. The $48.7 million figure is reported identically for fiscal 2024 and fiscal 2025, which is unusual, so we flag that the match merits a second look rather than treating it as settled.12
Costs are rising too. Incyte's cost of revenue grew from $255.0 million in fiscal 2023 to $312.1 million in 2024 and $372.1 million in 2025.13 In the third quarter alone it rose from $99.0 million in 2025 to $108.7 million in 2026.14 Earnings per share for fiscal 2023 was $2.65.15 Having cash does not mean having low costs.
Where revenue is already flowing
The dossier's cleanest revenue signal is BioArctic's royalty on Leqembi, which it develops with partner Eisai.16 Eisai reported Leqembi sales of JPY 29.3 billion in the second quarter of 2026, giving BioArctic a royalty of SEK 179 million, up about 10 percent from the same quarter in 2025.16 The comparison is distorted by a one-time stockpiling effect in China of around JPY 5.3 billion in Q2 2025. BioArctic says: "Excluding the stockpiling effect, royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year."16 The two growth rates, 10% and 43%, are both accurate. The second is the cleaner view of underlying demand, though it is the company's own adjustment.
Treat the longevity claims with care
Not every claim here deserves equal weight. Generation Lab says its injectable treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."17 The wording comes from a company fact sheet, as MIT Technology Review reported. Our measurement of MIT Technology Review's feed in this dataset is weak: only 6% of 16 checked claims held up.17 That figure says more about the small, noisy sample than about the publication. Still, we found no trial data behind the claim, so it stays a claim.
Others in the dossier are plans, not results. Ernexa says it remains on schedule to file an IND for ERNA-101 in the third quarter of 2026, with a first-in-human trial anticipated in the fourth quarter.18 Akari says its novel payload offers an exclusive opportunity in patients whose cancers have stopped responding to current antibody-drug conjugates, with Phase 1 planned for mid-2027.19 OPKO reported that its OPK8801001 showed about 20-fold greater growth hormone receptor antagonism than Pegvisomant, in vitro only.20 A lab result is not a patient result.
What to watch
- Whether Radical Numerics publishes anything beyond the first-patient statement, such as outcomes or a trial registration.1
- Scribe's first Phase 1 data, expected in the first half of 2027.6
- Ernexa's IND filing and Phase 1 start, which the company puts in the third and fourth quarters of 2026.18
- Whether Incyte's quarterly cash holds near $3 billion as its cost of revenue keeps climbing.10,14
- Further funding-target changes at large AI developers after OpenAI's $10 billion cut.3
The pattern in the verified data is plain. Funding is tightening, and the companies with finished trials or large cash balances are the ones this dossier can support. The early-stage and AI-led ones are still waiting for evidence.

